_id
69130b65ccc777a4e85d7c88
Ticker
KPTI
Name
Karyopharm Therapeutics Inc
Exchange
NASDAQ
Address
85 Wells Avenue, Newton, MA, United States, 02459-3298
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.karyopharm.com
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Last Close
7
Volume
34647
Current Price
6.98
Change
-0.28571428571427965
Last Updated
2025-12-01T10:00:22.730Z
Image
data:image/webp;base64,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
Ipo Date
2013-11-06T00:00:00.000Z
Market Cap
95825920
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-0.5
Sentiment Sources
2
Rating
4.1667
Target Price
14.6667
Strong Buy
2
Buy
3
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
44044000
Cost Of Revenue
2113000
Gross Profit
41931000
Operating Expenses
57151000
Operating Income
-15220000
Interest Expense
10455000
Pretax Income
-33093000
Net Income
-33127000
Eps
-3.8213173376398664
Dividends Per Share
-
Shares Outstanding
17050876
Income Tax Expense
34000
EBITDA
-22560000
Operating Margin
-34.55635273817092
Total Other Income Expense Net
-17873000
Cash
37672000
Short Term Investments
8205000
Receivables
31877000
Inventories
3966000
Total Current Assets
89746000
Property Plant Equipment
4802000
Total Assets
96232000
Payables
5392000
Short Term Debt
13672000
Long Term Debt
176743000
Total Liabilities
365490000
Equity
-269258000
Depreciation
-160000
Change In Working Capital
-8525000
Cash From Operations
-5860000
Capital Expenditures
0
Cash From Investing
4805000
Cash From Financing
0
Net Change In Cash
-39075000
PE
-
PB
-0.22472728758291305
ROE
12.303069918071143
ROA
-34.42410009144567
FCF
-5860000
Fcf Percent
-0.1330487694124058
Piotroski FScore
1
Health Score
25
Deep Value Investing Score
2
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
2
Momentum Investing Score
3
Net Net Investing Score
1
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
44044000
Quarters > 0 > income Statement > cost Of Revenue
2113000
Quarters > 0 > income Statement > gross Profit
41931000
Quarters > 0 > income Statement > operating Expenses
57151000
Quarters > 0 > income Statement > operating Income
-15220000
Quarters > 0 > income Statement > interest Expense
10455000
Quarters > 0 > income Statement > pretax Income
-33093000
Quarters > 0 > income Statement > net Income
-33127000
Quarters > 0 > income Statement > eps
-3.8213173376398664
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
8669000
Quarters > 0 > income Statement > income Tax Expense
34000
Quarters > 0 > income Statement > EBITDA
-22560000
Quarters > 0 > income Statement > operating Margin
-34.55635273817092
Quarters > 0 > income Statement > total Other Income Expense Net
-17873000
Quarters > 0 > balance Sheet > cash
37672000
Quarters > 0 > balance Sheet > short Term Investments
8205000
Quarters > 0 > balance Sheet > receivables
31877000
Quarters > 0 > balance Sheet > inventories
3966000
Quarters > 0 > balance Sheet > total Current Assets
89746000
Quarters > 0 > balance Sheet > property Plant Equipment
4802000
Quarters > 0 > balance Sheet > total Assets
96232000
Quarters > 0 > balance Sheet > payables
5392000
Quarters > 0 > balance Sheet > short Term Debt
13672000
Quarters > 0 > balance Sheet > long Term Debt
176743000
Quarters > 0 > balance Sheet > total Liabilities
365490000
Quarters > 0 > balance Sheet > equity
-269258000
Quarters > 0 > cash Flow > net Income
-33127000
Quarters > 0 > cash Flow > depreciation
-160000
Quarters > 0 > cash Flow > change In Working Capital
-8525000
Quarters > 0 > cash Flow > cash From Operations
-5860000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
4805000
Quarters > 0 > cash Flow > cash From Financing
0
Quarters > 0 > cash Flow > net Change In Cash
-39075000
Quarters > 0 > ratios > PE
-3.8213173376398664
Quarters > 0 > ratios > PB
-0.22472728758291305
Quarters > 0 > ratios > ROE
12.303069918071143
Quarters > 0 > ratios > ROA
-34.42410009144567
Quarters > 0 > ratios > FCF
-5860000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.1330487694124058
Quarters > 0 > health Score
25
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
37929000
Quarters > 1 > income Statement > cost Of Revenue
1051000
Quarters > 1 > income Statement > gross Profit
36878000
Quarters > 1 > income Statement > operating Expenses
61265000
Quarters > 1 > income Statement > operating Income
-24387000
Quarters > 1 > income Statement > interest Expense
11228000
Quarters > 1 > income Statement > pretax Income
-37212000
Quarters > 1 > income Statement > net Income
-37252000
Quarters > 1 > income Statement > eps
-4.321577726218098
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
8620000
Quarters > 1 > income Statement > income Tax Expense
40000
Quarters > 1 > income Statement > EBITDA
-25906000
Quarters > 1 > income Statement > operating Margin
-64.29644862769912
Quarters > 1 > income Statement > total Other Income Expense Net
-12825000
Quarters > 1 > balance Sheet > cash
38725000
Quarters > 1 > balance Sheet > short Term Investments
12972000
Quarters > 1 > balance Sheet > receivables
32932000
Quarters > 1 > balance Sheet > inventories
4992000
Quarters > 1 > balance Sheet > total Current Assets
97870000
Quarters > 1 > balance Sheet > property Plant Equipment
5325000
Quarters > 1 > balance Sheet > total Assets
104879000
Quarters > 1 > balance Sheet > payables
2597000
Quarters > 1 > balance Sheet > short Term Debt
32117000
Quarters > 1 > balance Sheet > long Term Debt
152250000
Quarters > 1 > balance Sheet > total Liabilities
343805000
Quarters > 1 > balance Sheet > equity
-238926000
Quarters > 1 > cash Flow > net Income
-37252000
Quarters > 1 > cash Flow > depreciation
-42000
Quarters > 1 > cash Flow > change In Working Capital
10050000
Quarters > 1 > cash Flow > cash From Operations
-18697000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
18285000
Quarters > 1 > cash Flow > cash From Financing
356000
Quarters > 1 > cash Flow > net Change In Cash
-48000
Quarters > 1 > ratios > PE
-4.321577726218098
Quarters > 1 > ratios > PB
-0.2518252513330487
Quarters > 1 > ratios > ROE
15.591438353297674
Quarters > 1 > ratios > ROA
-35.51902668789748
Quarters > 1 > ratios > FCF
-18697000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.4929473489941733
Quarters > 1 > health Score
27
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
30015000
Quarters > 2 > income Statement > cost Of Revenue
1301000
Quarters > 2 > income Statement > gross Profit
28714000
Quarters > 2 > income Statement > operating Expenses
61970000
Quarters > 2 > income Statement > operating Income
-33256000
Quarters > 2 > income Statement > interest Expense
10994000
Quarters > 2 > income Statement > pretax Income
-23426000
Quarters > 2 > income Statement > net Income
-23462000
Quarters > 2 > income Statement > eps
-2.7700118063754426
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
8470000
Quarters > 2 > income Statement > income Tax Expense
36000
Quarters > 2 > income Statement > EBITDA
-12354000
Quarters > 2 > income Statement > operating Margin
-110.79793436615026
Quarters > 2 > income Statement > total Other Income Expense Net
9830000
Quarters > 2 > balance Sheet > cash
38783000
Quarters > 2 > balance Sheet > short Term Investments
31158000
Quarters > 2 > balance Sheet > receivables
35243000
Quarters > 2 > balance Sheet > inventories
4769000
Quarters > 2 > balance Sheet > total Current Assets
120238000
Quarters > 2 > balance Sheet > property Plant Equipment
5799000
Quarters > 2 > balance Sheet > total Assets
127711000
Quarters > 2 > balance Sheet > payables
5872000
Quarters > 2 > balance Sheet > short Term Debt
25386000
Quarters > 2 > balance Sheet > long Term Debt
154832000
Quarters > 2 > balance Sheet > total Liabilities
333595000
Quarters > 2 > balance Sheet > equity
-205884000
Quarters > 2 > cash Flow > net Income
-23462000
Quarters > 2 > cash Flow > depreciation
78000
Quarters > 2 > cash Flow > change In Working Capital
-1525000
Quarters > 2 > cash Flow > cash From Operations
-38984000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
15288000
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-23691000
Quarters > 2 > ratios > PE
-2.7700118063754426
Quarters > 2 > ratios > PB
-0.28715490276077793
Quarters > 2 > ratios > ROE
11.395737405529328
Quarters > 2 > ratios > ROA
-18.371166148569817
Quarters > 2 > ratios > FCF
-38984000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-1.2988172580376478
Quarters > 2 > health Score
23
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
30542000
Quarters > 3 > income Statement > cost Of Revenue
1331000
Quarters > 3 > income Statement > gross Profit
29211000
Quarters > 3 > income Statement > operating Expenses
60492000
Quarters > 3 > income Statement > operating Income
-31281000
Quarters > 3 > income Statement > interest Expense
11204000
Quarters > 3 > income Statement > pretax Income
-30889000
Quarters > 3 > income Statement > net Income
-30780000
Quarters > 3 > income Statement > eps
-3.667749991480048
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
8392066
Quarters > 3 > income Statement > income Tax Expense
-109000
Quarters > 3 > income Statement > EBITDA
-19604000
Quarters > 3 > income Statement > operating Margin
-102.4196188854692
Quarters > 3 > income Statement > total Other Income Expense Net
392000
Quarters > 3 > balance Sheet > cash
62476000
Quarters > 3 > balance Sheet > short Term Investments
46236000
Quarters > 3 > balance Sheet > receivables
30766000
Quarters > 3 > balance Sheet > inventories
4739000
Quarters > 3 > balance Sheet > total Current Assets
156492000
Quarters > 3 > balance Sheet > property Plant Equipment
6284000
Quarters > 3 > balance Sheet > total Assets
164418000
Quarters > 3 > balance Sheet > payables
5107000
Quarters > 3 > balance Sheet > short Term Debt
24864000
Quarters > 3 > balance Sheet > long Term Debt
162948000
Quarters > 3 > balance Sheet > total Liabilities
350435000
Quarters > 3 > balance Sheet > equity
-186017000
Quarters > 3 > cash Flow > net Income
-30780000
Quarters > 3 > cash Flow > depreciation
2438000
Quarters > 3 > cash Flow > change In Working Capital
10084000
Quarters > 3 > cash Flow > cash From Operations
-25810000
Quarters > 3 > cash Flow > capital Expenditures
53000
Quarters > 3 > cash Flow > cash From Investing
14797000
Quarters > 3 > cash Flow > cash From Financing
680000
Quarters > 3 > cash Flow > net Change In Cash
-10353000
Quarters > 3 > ratios > PE
-3.667749991480048
Quarters > 3 > ratios > PB
-0.314899287054409
Quarters > 3 > ratios > ROE
16.546874748006903
Quarters > 3 > ratios > ROA
-18.72057803890085
Quarters > 3 > ratios > FCF
-25863000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.8468011263178574
Quarters > 3 > health Score
28
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
145237000
Annuals > 0 > income Statement > cost Of Revenue
6007000
Annuals > 0 > income Statement > gross Profit
139230000
Annuals > 0 > income Statement > operating Expenses
258673000
Annuals > 0 > income Statement > operating Income
-119443000
Annuals > 0 > income Statement > interest Expense
37422000
Annuals > 0 > income Statement > pretax Income
-76365000
Annuals > 0 > income Statement > net Income
-76422000
Annuals > 0 > income Statement > eps
-9.406711972466455
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
8124199
Annuals > 0 > income Statement > income Tax Expense
57000
Annuals > 0 > income Statement > EBITDA
-38603000
Annuals > 0 > income Statement > operating Margin
-82.24006279391615
Annuals > 0 > income Statement > total Other Income Expense Net
43078000
Annuals > 0 > balance Sheet > cash
62476000
Annuals > 0 > balance Sheet > short Term Investments
46236000
Annuals > 0 > balance Sheet > receivables
30766000
Annuals > 0 > balance Sheet > inventories
4739000
Annuals > 0 > balance Sheet > total Current Assets
156492000
Annuals > 0 > balance Sheet > property Plant Equipment
6284000
Annuals > 0 > balance Sheet > total Assets
164418000
Annuals > 0 > balance Sheet > payables
5107000
Annuals > 0 > balance Sheet > short Term Debt
24864000
Annuals > 0 > balance Sheet > long Term Debt
162948000
Annuals > 0 > balance Sheet > total Liabilities
350435000
Annuals > 0 > balance Sheet > equity
-186017000
Annuals > 0 > cash Flow > net Income
-76422000
Annuals > 0 > cash Flow > depreciation
340000
Annuals > 0 > cash Flow > change In Working Capital
-302000
Annuals > 0 > cash Flow > cash From Operations
-127486000
Annuals > 0 > cash Flow > capital Expenditures
142000
Annuals > 0 > cash Flow > cash From Investing
95473000
Annuals > 0 > cash Flow > cash From Financing
41646000
Annuals > 0 > cash Flow > net Change In Cash
9622000
Annuals > 0 > ratios > PE
-9.406711972466455
Annuals > 0 > ratios > PB
-0.2454506759059656
Annuals > 0 > ratios > ROE
41.08334184510018
Annuals > 0 > ratios > ROA
-46.48031237455753
Annuals > 0 > ratios > FCF
-127628000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.8787567906249785
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
146033000
Annuals > 1 > income Statement > cost Of Revenue
4942000
Annuals > 1 > income Statement > gross Profit
141091000
Annuals > 1 > income Statement > operating Expenses
270631000
Annuals > 1 > income Statement > operating Income
-129540000
Annuals > 1 > income Statement > interest Expense
23823000
Annuals > 1 > income Statement > pretax Income
-142776000
Annuals > 1 > income Statement > net Income
-143099000
Annuals > 1 > income Statement > eps
-18.792385760603818
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
7614733
Annuals > 1 > income Statement > income Tax Expense
323000
Annuals > 1 > income Statement > EBITDA
-118423000
Annuals > 1 > income Statement > operating Margin
-88.70597741606349
Annuals > 1 > income Statement > total Other Income Expense Net
-13236000
Annuals > 1 > balance Sheet > cash
52231000
Annuals > 1 > balance Sheet > short Term Investments
139212000
Annuals > 1 > balance Sheet > receivables
26962000
Annuals > 1 > balance Sheet > inventories
3043000
Annuals > 1 > balance Sheet > total Current Assets
233921000
Annuals > 1 > balance Sheet > property Plant Equipment
4882000
Annuals > 1 > balance Sheet > total Assets
240438000
Annuals > 1 > balance Sheet > payables
3123000
Annuals > 1 > balance Sheet > short Term Debt
3308000
Annuals > 1 > balance Sheet > long Term Debt
170919000
Annuals > 1 > balance Sheet > total Liabilities
376644000
Annuals > 1 > balance Sheet > equity
-136206000
Annuals > 1 > cash Flow > net Income
-143099000
Annuals > 1 > cash Flow > depreciation
530000
Annuals > 1 > cash Flow > change In Working Capital
31415000
Annuals > 1 > cash Flow > cash From Operations
-92723000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
7940000
Annuals > 1 > cash Flow > cash From Financing
1124000
Annuals > 1 > cash Flow > net Change In Cash
-83693000
Annuals > 1 > ratios > PE
-18.792385760603818
Annuals > 1 > ratios > PB
-0.3141917350190153
Annuals > 1 > ratios > ROE
105.06071685535146
Annuals > 1 > ratios > ROA
-59.51596669411657
Annuals > 1 > ratios > FCF
-92723000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-0.634945526011244
Annuals > 1 > health Score
31
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
157074000
Annuals > 2 > income Statement > cost Of Revenue
5213000
Annuals > 2 > income Statement > gross Profit
151861000
Annuals > 2 > income Statement > operating Expenses
294063000
Annuals > 2 > income Statement > operating Income
-142202000
Annuals > 2 > income Statement > interest Expense
24996000
Annuals > 2 > income Statement > pretax Income
-164922000
Annuals > 2 > income Statement > net Income
-165291000
Annuals > 2 > income Statement > eps
-30.28380382355215
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
5458066
Annuals > 2 > income Statement > income Tax Expense
369000
Annuals > 2 > income Statement > EBITDA
-139305000
Annuals > 2 > income Statement > operating Margin
-90.53185122935686
Annuals > 2 > income Statement > total Other Income Expense Net
-22720000
Annuals > 2 > balance Sheet > cash
135188000
Annuals > 2 > balance Sheet > short Term Investments
142779000
Annuals > 2 > balance Sheet > receivables
47086000
Annuals > 2 > balance Sheet > inventories
4224000
Annuals > 2 > balance Sheet > total Current Assets
350162000
Annuals > 2 > balance Sheet > property Plant Equipment
7377000
Annuals > 2 > balance Sheet > total Assets
358172000
Annuals > 2 > balance Sheet > payables
2773000
Annuals > 2 > balance Sheet > short Term Debt
2872000
Annuals > 2 > balance Sheet > long Term Debt
170105000
Annuals > 2 > balance Sheet > total Liabilities
374828000
Annuals > 2 > balance Sheet > equity
-16656000
Annuals > 2 > cash Flow > net Income
-165291000
Annuals > 2 > cash Flow > depreciation
621000
Annuals > 2 > cash Flow > change In Working Capital
-19989000
Annuals > 2 > cash Flow > cash From Operations
-149554000
Annuals > 2 > cash Flow > capital Expenditures
118000
Annuals > 2 > cash Flow > cash From Investing
-104256000
Annuals > 2 > cash Flow > cash From Financing
193738000
Annuals > 2 > cash Flow > net Change In Cash
-60560000
Annuals > 2 > ratios > PE
-30.28380382355215
Annuals > 2 > ratios > PB
-1.8416385038424592
Annuals > 2 > ratios > ROE
992.3811239193084
Annuals > 2 > ratios > ROA
-46.14849848676055
Annuals > 2 > ratios > FCF
-149672000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.9528757146313203
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
209819000
Annuals > 3 > income Statement > cost Of Revenue
3402000
Annuals > 3 > income Statement > gross Profit
206417000
Annuals > 3 > income Statement > operating Expenses
304688000
Annuals > 3 > income Statement > operating Income
-98271000
Annuals > 3 > income Statement > interest Expense
26046000
Annuals > 3 > income Statement > pretax Income
-123820000
Annuals > 3 > income Statement > net Income
-124088000
Annuals > 3 > income Statement > eps
-24.745674223302547
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
5014533
Annuals > 3 > income Statement > income Tax Expense
268000
Annuals > 3 > income Statement > EBITDA
-96985000
Annuals > 3 > income Statement > operating Margin
-46.83608252827437
Annuals > 3 > income Statement > total Other Income Expense Net
-25549000
Annuals > 3 > balance Sheet > cash
190459000
Annuals > 3 > balance Sheet > short Term Investments
38156000
Annuals > 3 > balance Sheet > receivables
22497000
Annuals > 3 > balance Sheet > inventories
4106000
Annuals > 3 > balance Sheet > total Current Assets
275606000
Annuals > 3 > balance Sheet > property Plant Equipment
9557000
Annuals > 3 > balance Sheet > total Assets
305305000
Annuals > 3 > balance Sheet > payables
1603000
Annuals > 3 > balance Sheet > short Term Debt
2316000
Annuals > 3 > balance Sheet > long Term Debt
169293000
Annuals > 3 > balance Sheet > total Liabilities
384978000
Annuals > 3 > balance Sheet > equity
-79673000
Annuals > 3 > cash Flow > net Income
-124088000
Annuals > 3 > cash Flow > depreciation
789000
Annuals > 3 > cash Flow > change In Working Capital
-23189000
Annuals > 3 > cash Flow > cash From Operations
-107116000
Annuals > 3 > cash Flow > capital Expenditures
5712000
Annuals > 3 > cash Flow > cash From Investing
141840000
Annuals > 3 > cash Flow > cash From Financing
73648000
Annuals > 3 > cash Flow > net Change In Cash
108324000
Annuals > 3 > ratios > PE
-24.745674223302547
Annuals > 3 > ratios > PB
-0.3537167605085788
Annuals > 3 > ratios > ROE
155.74661428589357
Annuals > 3 > ratios > ROA
-40.64394621771671
Annuals > 3 > ratios > FCF
-112828000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.5377396708591691
Annuals > 3 > health Score
30
Valuation > metrics > PE
-3.8213173376398664
Valuation > metrics > PB
-0.22472728758291305
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
12.303069918071143
Profitability > metrics > ROA
-36.91195150758808
Profitability > metrics > Net Margin
-0.7521342294069567
Profitability > final Score
25
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-1.455762792922047
Risk > final Score
24
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.707616449853126
Liquidity > metrics > Quick Ratio
4.4995803608896345
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
31
Prev Profitabilities > 1
23
Prev Profitabilities > 2
33
Prev Risks > 0
21
Prev Risks > 1
18
Prev Risks > 2
19
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:56:16.340Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-05
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-3.82
Earnings History > 0 > eps Estimate
-2.21
Earnings History > 0 > eps Difference
-1.61
Earnings History > 0 > surprise Percent
-72.8507
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-11
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-4.07
Earnings History > 1 > eps Estimate
-3.91
Earnings History > 1 > eps Difference
-0.16
Earnings History > 1 > surprise Percent
-4.0921
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-12
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-2.77
Earnings History > 2 > eps Estimate
-3.09
Earnings History > 2 > eps Difference
0.32
Earnings History > 2 > surprise Percent
10.356
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-19
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-3.6
Earnings History > 3 > eps Estimate
-4.03
Earnings History > 3 > eps Difference
0.43
Earnings History > 3 > surprise Percent
10.67
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-05
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-3.9
Earnings History > 4 > eps Estimate
-3.92
Earnings History > 4 > eps Difference
0.02
Earnings History > 4 > surprise Percent
0.5102
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-06
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
0.15
Earnings History > 5 > eps Estimate
-0.3
Earnings History > 5 > eps Difference
0.45
Earnings History > 5 > surprise Percent
150
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-08
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.32
Earnings History > 6 > eps Estimate
-0.33
Earnings History > 6 > eps Difference
0.01
Earnings History > 6 > surprise Percent
3.0303
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-02-29
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.36
Earnings History > 7 > eps Estimate
-0.31
Earnings History > 7 > eps Difference
-0.05
Earnings History > 7 > surprise Percent
-16.129
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-02
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.3
Earnings History > 8 > eps Estimate
-0.28
Earnings History > 8 > eps Difference
-0.02
Earnings History > 8 > surprise Percent
-7.1429
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-02
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
BeforeMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.29
Earnings History > 9 > eps Estimate
-0.34
Earnings History > 9 > eps Difference
0.05
Earnings History > 9 > surprise Percent
14.7059
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-05-04
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.3
Earnings History > 10 > eps Estimate
-0.37
Earnings History > 10 > eps Difference
0.07
Earnings History > 10 > surprise Percent
18.9189
Earnings History > 11 > period
2022-12-31
Earnings History > 11 > report Date
2023-02-15
Earnings History > 11 > date
2022-12-31
Earnings History > 11 > before After Market
BeforeMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-0.43
Earnings History > 11 > eps Estimate
-0.35
Earnings History > 11 > eps Difference
-0.08
Earnings History > 11 > surprise Percent
-22.8571
Earnings History > 12 > period
2022-09-30
Earnings History > 12 > report Date
2022-11-03
Earnings History > 12 > date
2022-09-30
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.45
Earnings History > 12 > eps Estimate
-0.57
Earnings History > 12 > eps Difference
0.12
Earnings History > 12 > surprise Percent
21.0526
Earnings History > 13 > period
2022-06-30
Earnings History > 13 > report Date
2022-08-04
Earnings History > 13 > date
2022-06-30
Earnings History > 13 > before After Market
BeforeMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.62
Earnings History > 13 > eps Estimate
-0.63
Earnings History > 13 > eps Difference
0.01
Earnings History > 13 > surprise Percent
1.5873
Earnings History > 14 > period
2022-03-31
Earnings History > 14 > report Date
2022-05-05
Earnings History > 14 > date
2022-03-31
Earnings History > 14 > before After Market
BeforeMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.53
Earnings History > 14 > eps Estimate
-0.63
Earnings History > 14 > eps Difference
0.1
Earnings History > 14 > surprise Percent
15.873
Earnings History > 15 > period
2021-12-31
Earnings History > 15 > report Date
2022-01-10
Earnings History > 15 > date
2021-12-31
Earnings History > 15 > before After Market
BeforeMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
0.46
Earnings History > 15 > eps Estimate
-0.52
Earnings History > 15 > eps Difference
0.98
Earnings History > 15 > surprise Percent
188.4615
Earnings History > 16 > period
2021-09-30
Earnings History > 16 > report Date
2021-11-03
Earnings History > 16 > date
2021-09-30
Earnings History > 16 > before After Market
BeforeMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-0.69
Earnings History > 16 > eps Estimate
-0.67
Earnings History > 16 > eps Difference
-0.02
Earnings History > 16 > surprise Percent
-2.9851
Earnings History > 17 > period
2021-06-30
Earnings History > 17 > report Date
2021-08-05
Earnings History > 17 > date
2021-06-30
Earnings History > 17 > before After Market
BeforeMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-0.71
Earnings History > 17 > eps Estimate
-0.75
Earnings History > 17 > eps Difference
0.04
Earnings History > 17 > surprise Percent
5.3333
Earnings History > 18 > period
2021-03-31
Earnings History > 18 > report Date
2021-05-03
Earnings History > 18 > date
2021-03-31
Earnings History > 18 > before After Market
BeforeMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-0.77
Earnings History > 18 > eps Estimate
-0.71
Earnings History > 18 > eps Difference
-0.06
Earnings History > 18 > surprise Percent
-8.4507
Earnings History > 19 > period
2020-12-31
Earnings History > 19 > report Date
2021-02-11
Earnings History > 19 > date
2020-12-31
Earnings History > 19 > before After Market
BeforeMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-0.59
Earnings History > 19 > eps Estimate
-0.59
Earnings History > 19 > eps Difference
0
Earnings History > 19 > surprise Percent
0
Earnings History > 20 > period
2020-09-30
Earnings History > 20 > report Date
2020-11-02
Earnings History > 20 > date
2020-09-30
Earnings History > 20 > before After Market
AfterMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.73
Earnings History > 20 > eps Estimate
-0.72
Earnings History > 20 > eps Difference
-0.01
Earnings History > 20 > surprise Percent
-1.3889
Earnings History > 21 > period
2020-06-30
Earnings History > 21 > report Date
2020-08-04
Earnings History > 21 > date
2020-06-30
Earnings History > 21 > before After Market
BeforeMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
-0.63
Earnings History > 21 > eps Estimate
-0.58
Earnings History > 21 > eps Difference
-0.05
Earnings History > 21 > surprise Percent
-8.6207
Earnings History > 22 > period
2020-03-31
Earnings History > 22 > report Date
2020-05-05
Earnings History > 22 > date
2020-03-31
Earnings History > 22 > before After Market
BeforeMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.78
Earnings History > 22 > eps Estimate
-0.69
Earnings History > 22 > eps Difference
-0.09
Earnings History > 22 > surprise Percent
-13.0435
Earnings History > 23 > period
2019-12-31
Earnings History > 23 > report Date
2020-02-13
Earnings History > 23 > date
2019-12-31
Earnings History > 23 > before After Market
BeforeMarket
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.76
Earnings History > 23 > eps Estimate
-0.67
Earnings History > 23 > eps Difference
-0.09
Earnings History > 23 > surprise Percent
-13.4328
Earnings History > 24 > period
2019-09-30
Earnings History > 24 > report Date
2019-11-04
Earnings History > 24 > date
2019-09-30
Earnings History > 24 > before After Market
BeforeMarket
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.67
Earnings History > 24 > eps Estimate
-0.83
Earnings History > 24 > eps Difference
0.16
Earnings History > 24 > surprise Percent
19.2771
Earnings History > 25 > period
2019-06-30
Earnings History > 25 > report Date
2019-08-06
Earnings History > 25 > date
2019-06-30
Earnings History > 25 > before After Market
BeforeMarket
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.71
Earnings History > 25 > eps Estimate
-0.98
Earnings History > 25 > eps Difference
0.27
Earnings History > 25 > surprise Percent
27.551
Earnings History > 26 > period
2019-03-31
Earnings History > 26 > report Date
2019-05-09
Earnings History > 26 > date
2019-03-31
Earnings History > 26 > before After Market
BeforeMarket
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-1.09
Earnings History > 26 > eps Estimate
-0.87
Earnings History > 26 > eps Difference
-0.22
Earnings History > 26 > surprise Percent
-25.2874
Earnings History > 27 > period
2018-12-31
Earnings History > 27 > report Date
2019-02-28
Earnings History > 27 > date
2018-12-31
Earnings History > 27 > before After Market
BeforeMarket
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.96
Earnings History > 27 > eps Estimate
-0.85
Earnings History > 27 > eps Difference
-0.11
Earnings History > 27 > surprise Percent
-12.9412
Earnings History > 28 > period
2018-09-30
Earnings History > 28 > report Date
2018-11-08
Earnings History > 28 > date
2018-09-30
Earnings History > 28 > before After Market
BeforeMarket
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-0.79
Earnings History > 28 > eps Estimate
-0.89
Earnings History > 28 > eps Difference
0.1
Earnings History > 28 > surprise Percent
11.236
Earnings History > 29 > period
2018-06-30
Earnings History > 29 > report Date
2018-08-07
Earnings History > 29 > date
2018-06-30
Earnings History > 29 > before After Market
BeforeMarket
Earnings History > 29 > currency
USD
Earnings History > 29 > eps Actual
-0.6
Earnings History > 29 > eps Estimate
-0.81
Earnings History > 29 > eps Difference
0.21
Earnings History > 29 > surprise Percent
25.9259
Earnings History > 30 > period
2018-03-31
Earnings History > 30 > report Date
2018-05-10
Earnings History > 30 > date
2018-03-31
Earnings History > 30 > before After Market
BeforeMarket
Earnings History > 30 > currency
USD
Earnings History > 30 > eps Actual
-0.78
Earnings History > 30 > eps Estimate
-0.62
Earnings History > 30 > eps Difference
-0.16
Earnings History > 30 > surprise Percent
-25.8065
Earnings History > 31 > period
2017-12-31
Earnings History > 31 > report Date
2018-03-15
Earnings History > 31 > date
2017-12-31
Earnings History > 31 > before After Market
BeforeMarket
Earnings History > 31 > currency
USD
Earnings History > 31 > eps Actual
-0.8
Earnings History > 31 > eps Estimate
-0.65
Earnings History > 31 > eps Difference
-0.15
Earnings History > 31 > surprise Percent
-23.0769
Earnings History > 32 > period
2017-09-30
Earnings History > 32 > report Date
2017-11-02
Earnings History > 32 > date
2017-09-30
Earnings History > 32 > before After Market
BeforeMarket
Earnings History > 32 > currency
USD
Earnings History > 32 > eps Actual
-0.65
Earnings History > 32 > eps Estimate
-0.64
Earnings History > 32 > eps Difference
-0.01
Earnings History > 32 > surprise Percent
-1.5625
Earnings History > 33 > period
2017-06-30
Earnings History > 33 > report Date
2017-08-08
Earnings History > 33 > date
2017-06-30
Earnings History > 33 > before After Market
BeforeMarket
Earnings History > 33 > currency
USD
Earnings History > 33 > eps Actual
-0.64
Earnings History > 33 > eps Estimate
-0.65
Earnings History > 33 > eps Difference
0.01
Earnings History > 33 > surprise Percent
1.5385
Earnings History > 34 > period
2017-03-31
Earnings History > 34 > report Date
2017-05-04
Earnings History > 34 > date
2017-03-31
Earnings History > 34 > before After Market
BeforeMarket
Earnings History > 34 > currency
USD
Earnings History > 34 > eps Actual
-0.71
Earnings History > 34 > eps Estimate
-0.67
Earnings History > 34 > eps Difference
-0.04
Earnings History > 34 > surprise Percent
-5.9701
Earnings History > 35 > period
2016-12-31
Earnings History > 35 > report Date
2017-03-16
Earnings History > 35 > date
2016-12-31
Earnings History > 35 > before After Market
BeforeMarket
Earnings History > 35 > currency
USD
Earnings History > 35 > eps Actual
-0.65
Earnings History > 35 > eps Estimate
-0.66
Earnings History > 35 > eps Difference
0.01
Earnings History > 35 > surprise Percent
1.5152
Earnings History > 36 > period
2016-09-30
Earnings History > 36 > report Date
2016-11-07
Earnings History > 36 > date
2016-09-30
Earnings History > 36 > before After Market
AfterMarket
Earnings History > 36 > currency
USD
Earnings History > 36 > eps Actual
-0.69
Earnings History > 36 > eps Estimate
-0.81
Earnings History > 36 > eps Difference
0.12
Earnings History > 36 > surprise Percent
14.8148
Earnings History > 37 > period
2016-06-30
Earnings History > 37 > report Date
2016-08-04
Earnings History > 37 > date
2016-06-30
Earnings History > 37 > before After Market
BeforeMarket
Earnings History > 37 > currency
USD
Earnings History > 37 > eps Actual
-0.84
Earnings History > 37 > eps Estimate
-0.76
Earnings History > 37 > eps Difference
-0.08
Earnings History > 37 > surprise Percent
-10.5263
Earnings History > 38 > period
2016-03-31
Earnings History > 38 > report Date
2016-05-09
Earnings History > 38 > date
2016-03-31
Earnings History > 38 > before After Market
BeforeMarket
Earnings History > 38 > currency
USD
Earnings History > 38 > eps Actual
-0.75
Earnings History > 38 > eps Estimate
-0.74
Earnings History > 38 > eps Difference
-0.01
Earnings History > 38 > surprise Percent
-1.3514
Earnings History > 39 > period
2015-12-31
Earnings History > 39 > report Date
2016-03-14
Earnings History > 39 > date
2015-12-31
Earnings History > 39 > before After Market
BeforeMarket
Earnings History > 39 > currency
USD
Earnings History > 39 > eps Actual
-0.81
Earnings History > 39 > eps Estimate
-0.82
Earnings History > 39 > eps Difference
0.01
Earnings History > 39 > surprise Percent
1.2195
Earnings History > 40 > period
2015-09-30
Earnings History > 40 > report Date
2015-11-09
Earnings History > 40 > date
2015-09-30
Earnings History > 40 > before After Market
BeforeMarket
Earnings History > 40 > currency
USD
Earnings History > 40 > eps Actual
-0.85
Earnings History > 40 > eps Estimate
-0.87
Earnings History > 40 > eps Difference
0.02
Earnings History > 40 > surprise Percent
2.2989
Earnings History > 41 > period
2015-06-30
Earnings History > 41 > report Date
2015-08-10
Earnings History > 41 > date
2015-06-30
Earnings History > 41 > before After Market
BeforeMarket
Earnings History > 41 > currency
USD
Earnings History > 41 > eps Actual
-0.92
Earnings History > 41 > eps Estimate
-0.77
Earnings History > 41 > eps Difference
-0.15
Earnings History > 41 > surprise Percent
-19.4805
Earnings History > 42 > period
2015-03-31
Earnings History > 42 > report Date
2015-05-11
Earnings History > 42 > date
2015-03-31
Earnings History > 42 > before After Market
BeforeMarket
Earnings History > 42 > currency
USD
Earnings History > 42 > eps Actual
-0.74
Earnings History > 42 > eps Estimate
-0.73
Earnings History > 42 > eps Difference
-0.01
Earnings History > 42 > surprise Percent
-1.3699
Earnings History > 43 > period
2014-12-31
Earnings History > 43 > report Date
2015-03-11
Earnings History > 43 > date
2014-12-31
Earnings History > 43 > before After Market
AfterMarket
Earnings History > 43 > currency
USD
Earnings History > 43 > eps Actual
-0.79
Earnings History > 43 > eps Estimate
-0.65
Earnings History > 43 > eps Difference
-0.14
Earnings History > 43 > surprise Percent
-21.5385
Earnings History > 44 > period
2014-09-30
Earnings History > 44 > report Date
2014-11-10
Earnings History > 44 > date
2014-09-30
Earnings History > 44 > before After Market
BeforeMarket
Earnings History > 44 > currency
USD
Earnings History > 44 > eps Actual
-0.61
Earnings History > 44 > eps Estimate
-0.52
Earnings History > 44 > eps Difference
-0.09
Earnings History > 44 > surprise Percent
-17.3077
Earnings History > 45 > period
2014-06-30
Earnings History > 45 > report Date
2014-08-07
Earnings History > 45 > date
2014-06-30
Earnings History > 45 > before After Market
-
Earnings History > 45 > currency
USD
Earnings History > 45 > eps Actual
-0.55
Earnings History > 45 > eps Estimate
-0.49
Earnings History > 45 > eps Difference
-0.06
Earnings History > 45 > surprise Percent
-12.2449
Earnings History > 46 > period
2014-03-31
Earnings History > 46 > report Date
2014-05-07
Earnings History > 46 > date
2014-03-31
Earnings History > 46 > before After Market
-
Earnings History > 46 > currency
USD
Earnings History > 46 > eps Actual
-0.46
Earnings History > 46 > eps Estimate
-0.47
Earnings History > 46 > eps Difference
0.01
Earnings History > 46 > surprise Percent
2.1277
Earnings History > 47 > period
2013-12-31
Earnings History > 47 > report Date
2014-03-05
Earnings History > 47 > date
2013-12-31
Earnings History > 47 > before After Market
-
Earnings History > 47 > currency
USD
Earnings History > 47 > eps Actual
-2
Earnings History > 47 > eps Estimate
-0.34
Earnings History > 47 > eps Difference
-1.66
Earnings History > 47 > surprise Percent
-488.2353
Earnings History > 48 > period
2013-09-30
Earnings History > 48 > report Date
2013-11-27
Earnings History > 48 > date
2013-09-30
Earnings History > 48 > before After Market
-
Earnings History > 48 > currency
USD
Earnings History > 48 > eps Actual
-4.6997
Earnings History > 48 > eps Estimate
-
Earnings History > 48 > eps Difference
0
Earnings History > 48 > surprise Percent
-
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABreakouts Watch: Is WBTN stock a contrarian buy - July 2025 Momentum & Fast Moving Market Watchlists moha.gov.vn
Read more →Momentum Shift: Will KPTI stock benefit from AI adoption - July 2025 Reactions & Risk Controlled Stock Pick Alerts moha.gov.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$14.6667
Analyst Picks
Strong Buy
2
Buy
3
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bearish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 65.49% of the total shares of Karyopharm Therapeutics Inc
1.
T. Rowe Price Investment Management,Inc.(8.4044%)
since
2025/06/30
2.
Vanguard Group Inc(5.9768%)
since
2025/06/30
3.
T. Rowe Price Small-Cap Value(5.1349%)
since
2025/07/31
4.
Adage Capital Partners Gp LLC(4.8588%)
since
2025/06/30
5.
T. Rowe Price U.S. SC Value Eq Tr-D(3.0408%)
since
2025/06/30
6.
Eversept Partners, LLC(2.9656%)
since
2025/06/30
7.
JPMorgan Chase & Co(2.9574%)
since
2025/06/30
8.
BlackRock Inc(2.729%)
since
2025/06/30
9.
Vanguard Total Stock Mkt Idx Inv(2.5743%)
since
2025/07/31
10.
Citadel Advisors Llc(2.3847%)
since
2025/06/30
11.
Palo Alto Investors, LLC(2.1671%)
since
2025/06/30
12.
Bank of America Corp(1.9436%)
since
2025/06/30
13.
UBS Group AG(1.8671%)
since
2025/06/30
14.
Catalio Capital Management, LP(1.6839%)
since
2025/06/30
15.
Avidity Partners Management LP(1.5519%)
since
2025/06/30
16.
Vanguard Explorer Inv(1.5439%)
since
2025/06/30
17.
Marshall Wace Asset Management Ltd(1.4813%)
since
2025/06/30
18.
Goldman Sachs Group Inc(1.2617%)
since
2025/06/30
19.
CAM Group Holding A/S(1.1532%)
since
2025/06/30
20.
C WorldWide Healthcare Select 1A(1.1532%)
since
2025/07/31
21.
Group One Trading, LP(1.129%)
since
2025/06/30
22.
Geode Capital Management, LLC(1.0591%)
since
2025/06/30
23.
Vanguard Institutional Extnd Mkt Idx Tr(0.9309%)
since
2025/07/31
24.
Silverback Aset Management LLC(0.8073%)
since
2025/06/30
25.
Renaissance Technologies Corp(0.759%)
since
2025/06/30
26.
Altium Capital Management, LP(0.5689%)
since
2025/03/31
27.
BlackRock Advantage Small Cap Core Instl(0.5376%)
since
2025/07/31
28.
Fidelity Extended Market Index(0.5231%)
since
2025/07/31
29.
Macquarie Healthcare I(0.3844%)
since
2025/07/31
30.
Bridgeway Ultra-Small Company(0.321%)
since
2025/06/30
31.
Vanguard VIF Small Co Gr(0.2796%)
since
2025/06/30
32.
Extended Equity Market Fund K(0.2316%)
since
2025/06/30
33.
T. Rowe Price U.S. Equities Tr(0.2038%)
since
2025/06/30
34.
iShares Micro-Cap ETF(0.2026%)
since
2025/08/31
35.
Fidelity Total Market Index(0.1706%)
since
2025/07/31
36.
Goldman Sachs Absolute Ret Trckr Instl(0.1598%)
since
2025/06/30
37.
Blackrock Russell 2000 Alpha Tilts Fd A(0.1581%)
since
2025/06/30
38.
Fidelity Series Total Market Index(0.142%)
since
2025/07/31
39.
Vanguard Instl Ttl Stck Mkt Idx Tr(0.0636%)
since
2024/12/31
40.
NT Ext Eq Mkt Indx Fd DC Lend T3(0.0291%)
since
2024/12/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-3.82
EPS Estimate
-2.21
EPS Difference
-1.61
Surprise Percent
-72.8507%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.